RecruitingPhase 2NCT07072468

Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)

Studying Paraneoplastic neurologic syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
VM Therapeutics LLC
Principal Investigator
Clinical Development
VM Therapeutics LLC
Intervention
VMD-3866 Gel(drug)
Enrollment
16 target
Eligibility
18-80 years · All sexes
Timeline
2025 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07072468 on ClinicalTrials.gov

Other trials for Paraneoplastic neurologic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Paraneoplastic neurologic syndrome →

← Back to all trials